• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Vaikuttavuussaatio

Vaikuttavuussaatio

Vaikuttavuussäätiö vahvistaa ja tukee huippututkimuksen vaikuttavuutta ja elinkeinoelämän yhteyksiä.

  • FI
  • EN
  • Front page
  • Funding
    • Open calls
    • Previous calls
    • Projects funded
  • Foundation
    • About
    • Annual reports
    • Blog
    • Assessment of Impact
  • Publications
  • Contact

Immunotherapy can revolutionize the cancer therapy market

Immunotherapy can revolutionize the cancer therapy market

30.5.2021 by vaikuttavuussaatio

« back to Annual Report

Project title: Improving immuno-oncology tools to fight cancer: the use of complex immune organoids for testing the efficacy of peptides coated oncolytic viruses (PeptiCRAd / PeptiENV)
Academic partner: University of Helsinki
Principal investigator: Professor Vincenzo Cerullo
Postdoc researcher: Mikaela Grönholm
Industry partner: Valo Therapeutics

The Finnish start-up company Valo Therapeutics and the Immuno Viro Therapy lab at the University of Helsinki are working to develop a 3D model that can predict the effects of immunotherapy in individual patients.

Common usage often classifies cancers based on their site of origin in the body: breast cancer, lung cancer, skin cancer. However, the same cancer can be a very different disease for different individuals.

“In fact it’s true to say that every patient has their own disease,” says oncology researcher Mikaela Grönholm from the Immuno Viro Therapy team at the University of Helsinki. This is why the current therapeutic approach of destroying the tumour at a certain body site is becoming outdated. A new strategy is emerging with the evolution of immunotherapy, which is focused on activating the patient’s own immune system.

Immunotherapy has achieved excellent results in the treatment of melanoma or skin cancer, for instance. But Mikaela says there are currently two obstacles to the wider adoption of immunotherapy: “We still know very little about who can benefit from the therapy and who can’t. And secondly, developing and testing treatments is an expensive process and we don’t yet have good testing models in place.”

The Finnish start-up company Valo Therapeutics is working closely with the Immuno Viro Therapy team at the University of Helsinki to find a solution to this testing problem. They are growing 3D mini-tumours that include both cancer tissue, the cancer microenvironment and the patient’s own immune cells. The team are also involved in the Academy of Finland’s iCAN cancer flagship project (Digital Precision Medicine platform).

It is noteworthy that the model is entirely anthropogenic and therefore works in the exact same way as in the human body. “The model will benefit everyone working on immunotherapy,” says Mikaela Grönholm, who is involved in the project as postdoc researcher. 

Business cooperation opens up interesting research questions

Grönholm says that collaboration between an academic partner and a start-up company brings together the unique strengths of both parties and for the researcher provides an excellent vantage point over the way the business operates. “In the academic world you’re allowed to take risks, to be curious and to experiment, whereas a business will set specific targets for research and formulate research questions that are interesting from a drug development point of view.”

When researchers get to work with a start-up company, they also get the opportunity to influence and express their views about the technology under development. “I’m involved in creating tools that are immediately put to use in the company.”

Grönholm believes that collaborations between academia and business companies could still be expanded. That is why incentives such as FRIF’s Tandem funding scheme are so important. 

Promising results from collaboration

The 3D model created by Valo Therapeutics and the University of Helsinki team is applicable to all aspects of immunotherapy development. What is more, the project will provide crucial information about the applicability of immunotherapy for different people. It makes use of the oncolytic viruses manufactured by Valo Therapeutics, which trigger the organism’s immune responses in the body. The team have now been using these viruses to test their model, and the results are promising. The next step is to raise the bar and enter more variables into the model.

Start-up companies and researchers both share a strong passion for problem-solving. “It’s unbelievable what cancer can do to the body. That is what makes cancer research so fascinating and so challenging. I want to find ways to cure cancer,” Grönholm says. 

  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

Filed Under: Annual Report 2020

Footer

Vaikuttavuussäätiö

Mariankatu 5A, 00170 Helsinki
+358 40 767 1631
petro (at) vaikuttavuussaatio.fi

Laskutustiedot →

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Tietosuojaseloste →

Copyright © 2022 Vaikuttavuussäätiö

By accepting cookies, you make your service experience as smooth as possible. Some cookies are used for statistical purposes and others are related to services provided by third parties. By selecting ACCEPT, you agree to the use of cookies. Read moreSettings REJECTACCEPT
Cookiesettings

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional1 yearThe cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
viewed_cookie_policy1 yearThe cookie is set by the GDPR Cookie Consent plugin to store whether or not the user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
bcookie2 yearsLinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
bscookie2 yearsLinkedIn sets this cookie to store performed actions on the website.
langsessionLinkedIn sets this cookie to remember a user's language setting.
lidc1 dayLinkedIn sets the lidc cookie to facilitate data center selection.
UserMatchHistory1 monthLinkedIn sets this cookie for LinkedIn Ads ID syncing.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_MEFLNRCR5S2 yearsThis cookie is installed by Google Analytics.
_gat_UA-160708278-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gcl_au3 monthsProvided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
_fbp3 monthsThis cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
fr3 monthsFacebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
VISITOR_INFO1_LIVE5 months 27 daysA cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSCsessionYSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devicesneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-idneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
AnalyticsSyncHistory1 monthNo description
li_gc2 yearsNo description
Save & Accept